Kodiak Sciences Inc.
Tremor tracks 3 of its cancer trials.
Company-wide warning signs
These add points to every one of this company's trials.
Trials
- KODKodiak Sciences Inc0Calm
A Study to Evaluate the Efficacy and Safety of Tabirafusp Tedromer Compared to Aflibercept in Participants With DME - ALTO
Signing up patientsPhase 3910 patientsMain results: Aug 31, 2028 - KODKodiak Sciences Inc0Calm
A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PINNACLE
Signing up patientsPhase 3300 patientsMain results: Feb 2027 - KODKodiak Sciences Inc0Calm
A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAK
Signing up patientsPhase 3600 patientsMain results: Apr 2027
Key executives leaving
From the last 12 months of the company's SEC reports.
Insider trades (last 6 months)
“Insiders” are executives, board members, and big shareholders. Many of their sales are pre-planned: scheduled months ahead under a legal plan (called 10b5-1), so they usually say little. Tremor only counts sales that weren't pre-planned.
10 sales (0 not pre-planned) · 86 purchases
- BAKER BROS. ADVISORS LPBoard member · Nov 5, 2026Bought 4,703 sharesabout $463 thousand ·
- BAKER BROS. ADVISORS LPBoard member · Nov 5, 2026Bought 81,729 sharesabout $8.1 million ·
- BAKER BROS. ADVISORS LPBoard member · Nov 4, 2026Bought 8,742 sharesabout $861 thousand ·
- BAKER BROS. ADVISORS LPBoard member · Nov 4, 2026Bought 151,916 sharesabout $15.0 million ·
- BORGESON JOHN A.Chief Financial Officer · Oct 21, 2026Sold 8,514 sharesabout $746 thousand · pre-planned
- BORGESON JOHN A.Chief Financial Officer · Oct 21, 2026
Recent SEC filings
Public companies must report important news and their finances to the SEC, the US agency that oversees the stock market.